Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 11Colorectal Neoplasms 7Gastrointestinal Neoplasms 3Colonic Neoplasms 3Rectal Neoplasms 2Cholangiocarcinoma 2Untreated Resectable Pancreatic Adenocarcinoma 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Cancer Resectable 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Klatskin Tumor 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Oxaliplatin 30Gemcitabine 28Fluorouracil 27Capecitabine 22Leucovorin 19pembrolizumab 15130-nm albumin-bound paclitaxel 13Irinotecan 12Cisplatin 11Bevacizumab 11Albumin-Bound Paclitaxel 11Paclitaxel 10Ramucirumab 8Radiotherapy 8Docetaxel 8Nivolumab 7trastuzumab deruxtecan 6Cyclophosphamide 6Taxes 5Drug Therapy 5durvalumab 4Trastuzumab 4Metformin 4zolbetuximab 3spartalizumab 3folfirinox 3cemiplimab 3XELOX 3Surgical Procedures, Operative 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × Hydroxychloroquine × Gastrointestinal × Clear all
NCT01206530 2019-04-18

FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer

Abramson Cancer Center at Penn Medicine

Phase 1/2 Completed
50 enrolled
Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡